Randall W. Barton, PhD.
Chief Scientific Officer

Randall W. Barton has over 20 years of experience in drug discovery and early stage development of both small molecule and biological drug candidates in immunology, virology and cardiovascular diseases at Boehringer Ingelheim Pharmaceuticals. Dr. Barton has authored over 70 scientific publications, and has been the principal investigator leading to 5 patents, and 3 patent applications. Dr. Barton has a Ph.D. in biochemistry from the University of Tennessee at Oak Ridge National Laboratory.

Jayant Tatake, PhD.
Vice President, R&D

Jay Tatake is an organic chemist with over 25 years of experience in Research and Process Development of fine chemicals. His experience encompasses production scale-up, and large scale manufacture of raw materials for pharmaceuticals. Before joining NanoViricides, Inc., he was Assistant Director of Analytical R&D at Interpharm, Inc. Prior to that, he was Director of Analytical Services at Pharmax Group, Inc. Dr. Tatake has several years experience in Analytical methods development and Quality Control in cGMP environment. His experience includes bio-analytical methods development. Prior to Pharmax Group, he was in the Pharmacology Department, University of Connecticut Health Center, where he synthesized and developed novel bio-conjugates for bio-diagnostics applications.

Jay has a Ph.D. from Department of Chemical Technology, University of Bombay. He is a member of American Chemical Society (ACS). He has published several papers in leading journals and is a co-inventor of several patents.

Krishna Menon, PhD, VMD, MRCS
Chief Regulatory Officer, Consulting

Dr. Menon was originally trained as a veterinary surgeon. He was Director of Agriculture for Cayman Islands, in the British Caribbean during 1978-1981. Thereafter he came to the Dana Farber Cancer Research Institute and obtained a PhD in Pharmacology in 1984 from Harvard University. He worked under the direction of Nobel Laureate Dr. Tom Frye. His PhD work involved anti-folate therapy of various cancers, which has led to the extremely important drugs, methotrexate and recently, the blockbuster Alimta. He was Research Scientist at Dana Farber between 1985 to 1990. He was Senior Research Scientist, In Vivo Research (Cancer), at Bayer Pharmaceuticals (Miles Laboratories) during 1991-1993. He had his own veterinary oncology and drug development consultancy practice during 1994. Thereafter, he was Group Leader, Cancer In Vivo Research and Clinical Development, at Eli Lilly and Company during 1995-2001. He was responsible for the development of the anticancer drugs Cryptophycin and the blockbusters, Gemzar and Alimta. He also helped developed another seven compounds at Lilly which are in late clinical phases at present. He has also contributed to the development of an anti-infective drug by Nexus Pharmaceuticals.

Dr. Menon won the Employee of the Year, President's Award at Eli Lilly for 1999. Later, he was the Director of Operations for the ALS Therapy Development Foundation during 2001-2002 (ALS is acute lateral sclerosis, a disease related to Lou Gehrig's Syndrome). He is a Founder and Board Member of KARD Scientific, Cambridge, MA; KARD Inc., Wilmington, MA; as well as KARD Scientific India, Bangalore, India and KARD Medics, Mumbai, India. He is a Director of Biological Supplies, New York, NY. He is a Member of the Scientific Advisory Board of Nexus Pharmaceuticals, Philadelphia, PA and TheraCour Pharma, Inc., West Haven, CT. He is Distinguished Scientist and Scientific Diplomat for GPC-Biotech, Germany. Dr. Menon is a Certified Toxicologist and a Member of the American Association of Toxicology. He holds a VMD from Triniti University, Peru, and MRCS from Royal University of Copenhagen. He is a practicing veterinary surgeon and human physician, licensed in various countries.

Dr. Menon participated in the development of 8 International and 3 US patents, including the one for Alimta. He has been responsible for 7 FDA approved drugs, 3 of which are blockbusters. While at Harvard, he conducted pre-clinical studies on the important anti-HIV drug, AZT. He is well known for his grasp of scientific and regulatory matters in taking a compound from the Chemist's bench to FDA approval. He is regularly invited to lecture across the globe on the drug development process and the regulatory landscape.